ProShare Advisors’s Shockwave Medical, Inc. Common Stock SWAV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-1,868
Closed -$608K 2040
2024
Q1
$608K Sell
1,868
-150
-7% -$36.8K ﹤0.01% 977
2023
Q4
$385K Sell
2,018
-11
-0.5% -$2.08K ﹤0.01% 1218
2023
Q3
$404K Sell
2,029
-160
-7% -$37.8K ﹤0.01% 1027
2023
Q2
$625K Sell
2,189
-4,232
-66% -$1.18M ﹤0.01% 862
2023
Q1
$1.39M Sell
6,421
-934
-13% -$182K ﹤0.01% 688
2022
Q4
$1.51M Buy
7,355
+895
+14% +$226K 0.01% 664
2022
Q3
$1.8M Sell
6,460
-93
-1% -$23.6K 0.01% 634
2022
Q2
$1.25M Sell
6,553
-581
-8% -$103K ﹤0.01% 716
2022
Q1
$1.48M Sell
7,134
-1,121
-14% -$185K ﹤0.01% 794
2021
Q4
$1.47M Buy
8,255
+3,097
+60% +$611K ﹤0.01% 856
2021
Q3
$1.06M Sell
5,158
-3,597
-41% -$706K ﹤0.01% 888
2021
Q2
$1.66M Buy
8,755
+1,152
+15% +$189K ﹤0.01% 788
2021
Q1
$990K Buy
7,603
+1,302
+21% +$156K ﹤0.01% 988
2020
Q4
$654K Buy
6,301
+2,817
+81% +$244K ﹤0.01% 1102
2020
Q3
$264K Buy
+3,484
New +$198K ﹤0.01% 1265

Other funds holding SWAV

ProShare Advisors's SWAV Position: Q2 2024 in Review

ProShare Advisors sold out of Shockwave Medical, Inc. Common Stock (SWAV) in Q2 2024, closing a stake of 1,868 shares — an estimated $608K sold.

ProShare Advisors first reported a position in SWAV in Q3 2020 and held it in 15 quarters. The position peaked at $1.8M in Q3 2022. 7 funds tracked by Wall St. Rank hold SWAV as of Q2 2024.

  • ProShare Advisors reported no remaining Shockwave Medical, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • ProShare Advisors sold 1,868 Shockwave Medical, Inc. Common Stock shares in Q2 2024, an estimated $608K.
  • ProShare Advisors first reported a position in Shockwave Medical, Inc. Common Stock in Q3 2020 and held it in 15 quarters.
  • ProShare Advisors's Shockwave Medical, Inc. Common Stock position peaked at $1.8M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Shockwave Medical, Inc. Common Stock as of Q2 2024.

Based on ProShare Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.